# Kite Pharma

the FDA approved a label update for Yescarta (axicabtagene ciloleucel) in February 2026, reinforcing its lead in CD19 CAR-T for large B-cell lymphoma, alongside Tecartus for mantle-cell and ALL.

Source: https://en.bioecon.ru/companies/kite-pharma/
Updated: 2026-07-11

- Country: United States

## Technologies

- [CAR-T cell therapy](https://en.bioecon.ru/technology/car-t-cell-therapy/)